Logo image of BCAB

BIOATLA INC (BCAB) Stock Fundamental Analysis

NASDAQ:BCAB - Nasdaq - US09077B1044 - Common Stock - Currency: USD

0.4819  +0.03 (+5.52%)

After market: 0.47 -0.01 (-2.47%)

Fundamental Rating

3

Overall BCAB gets a fundamental rating of 3 out of 10. We evaluated BCAB against 558 industry peers in the Biotechnology industry. While BCAB seems to be doing ok healthwise, there are quite some concerns on its profitability. BCAB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BCAB has reported negative net income.
BCAB had a negative operating cash flow in the past year.
In the past 5 years BCAB always reported negative net income.
In the past 5 years BCAB always reported negative operating cash flow.
BCAB Yearly Net Income VS EBIT VS OCF VS FCFBCAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of BCAB (-133.10%) is worse than 83.69% of its industry peers.
BCAB has a worse Return On Equity (-489.14%) than 77.78% of its industry peers.
Industry RankSector Rank
ROA -133.1%
ROE -489.14%
ROIC N/A
ROA(3y)-94.49%
ROA(5y)-67.12%
ROE(3y)-240.96%
ROE(5y)-157.04%
ROIC(3y)N/A
ROIC(5y)N/A
BCAB Yearly ROA, ROE, ROICBCAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAB Yearly Profit, Operating, Gross MarginsBCAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

BCAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BCAB has more shares outstanding
The number of shares outstanding for BCAB has been increased compared to 5 years ago.
There is no outstanding debt for BCAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCAB Yearly Shares OutstandingBCAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
BCAB Yearly Total Debt VS Total AssetsBCAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

BCAB has an Altman-Z score of -16.17. This is a bad value and indicates that BCAB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BCAB (-16.17) is worse than 81.72% of its industry peers.
There is no outstanding debt for BCAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.17
ROIC/WACCN/A
WACC9.85%
BCAB Yearly LT Debt VS Equity VS FCFBCAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

BCAB has a Current Ratio of 3.52. This indicates that BCAB is financially healthy and has no problem in meeting its short term obligations.
BCAB has a Current ratio (3.52) which is comparable to the rest of the industry.
BCAB has a Quick Ratio of 3.52. This indicates that BCAB is financially healthy and has no problem in meeting its short term obligations.
BCAB has a Quick ratio (3.52) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.52
Quick Ratio 3.52
BCAB Yearly Current Assets VS Current LiabilitesBCAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

BCAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.00%, which is quite impressive.
The Revenue has been growing by 16.17% on average over the past years. This is quite good.
EPS 1Y (TTM)51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
Revenue 1Y (TTM)N/A
Revenue growth 3Y253.04%
Revenue growth 5Y16.17%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.05% on average over the next years.
The Revenue is expected to grow by 49.79% on average over the next years. This is a very strong growth
EPS Next Y20.67%
EPS Next 2Y6.49%
EPS Next 3Y7.08%
EPS Next 5Y6.05%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y49.79%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BCAB Yearly Revenue VS EstimatesBCAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
BCAB Yearly EPS VS EstimatesBCAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCAB. In the last year negative earnings were reported.
Also next year BCAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAB Price Earnings VS Forward Price EarningsBCAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAB Per share dataBCAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.49%
EPS Next 3Y7.08%

More info and screens

0

5. Dividend

5.1 Amount

BCAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOATLA INC

NASDAQ:BCAB (6/6/2025, 8:00:01 PM)

After market: 0.47 -0.01 (-2.47%)

0.4819

+0.03 (+5.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-06 2025-08-06
Inst Owners48.4%
Inst Owner Change-29.91%
Ins Owners6.05%
Ins Owner Change20.22%
Market Cap28.15M
Analysts84
Price Target8.5 (1663.85%)
Short Float %8.33%
Short Ratio7.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.34%
Min EPS beat(2)22.6%
Max EPS beat(2)40.09%
EPS beat(4)4
Avg EPS beat(4)19.34%
Min EPS beat(4)1.51%
Max EPS beat(4)40.09%
EPS beat(8)7
Avg EPS beat(8)14.61%
EPS beat(12)10
Avg EPS beat(12)11.55%
EPS beat(16)11
Avg EPS beat(16)5.14%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.7%
EPS NY rev (1m)10.58%
EPS NY rev (3m)14.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.56
P/FCF N/A
P/OCF N/A
P/B 1.97
P/tB 1.97
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.19
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -133.1%
ROE -489.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-94.49%
ROA(5y)-67.12%
ROE(3y)-240.96%
ROE(5y)-157.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.52
Quick Ratio 3.52
Altman-Z -16.17
F-Score3
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)10.18%
Cap/Depr(5y)31.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
EPS Next Y20.67%
EPS Next 2Y6.49%
EPS Next 3Y7.08%
EPS Next 5Y6.05%
Revenue 1Y (TTM)N/A
Revenue growth 3Y253.04%
Revenue growth 5Y16.17%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y49.79%
EBIT growth 1Y42.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.84%
OCF growth 3YN/A
OCF growth 5YN/A